



# IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 October 2018

## Completion of Rights Issue

Imagion Biosystems Limited (the **Company**) advises that the 1-for-2 pro-rata non-renounceable rights issue at an issue price of \$0.04 (**Offer**) as announced by the Company on 20 September 2018 closed on Wednesday 17 October 2018, with the following results (which remain subject to cheque clearances):

<b>Maximum New Shares available under the Offer</b>	107,147,608 Shares
<b>Number of New Entitlement Shares applied for under the Offer</b>	8,356,748 Shares
<b>Number of New Additional Shares applied for under the Offer</b>	1,916,350 Shares
<b>Total New Shares applied for under the Offer</b>	10,273,098 Shares
<b>Issue price per Share under Offer</b>	\$0.04
<b>Total Application funds received under Offer</b>	\$410,924
<b>Number of Shortfall Shares</b>	96,874,510 Shares

The Company will issue and allot the New Shares applied for under the Offer on 24 October 2018. The New Shares issued under the Offer will be fully paid and will rank equally with the Company's existing Shares. The Company will make an application to the ASX for official quotation of the New Shares.

The Directors reserve the right to place any or all of the remaining Shortfall Shares at the Offer price at their discretion to sophisticated and/or professional investors (under section 708 of the *Corporations Act 2001* (Cth) (the **Act**)) within 3 months of the close of the Offer (**Shortfall Placement**).

The Shortfall Placement will be managed by the Lead Manager to the Offer, Pamplona Corporate Pty Ltd, pursuant to a mandate agreement. Under the key terms of the mandate agreement (which are set out in the Offer Document), the Lead Manager was entitled to receive a management fee of \$25,000, and a selling fee of 6.0% of the funds raised under the Shortfall Placement (**Selling Fee**). Subsequent to the date of the Offer Document, the Lead Manager and the Company have agreed that the Selling Fee may be paid in cash or equity, or a combination of them. In particular, the Selling Fee may be paid by the Company as follows:

- by payment of cash equal to 6.0% of the funds raised under the Shortfall Placement (**Cash Fee**); or
- by the issue of Options exercisable at \$0.06, expiring 24 months after date of issue, on the basis of 0.4 Options per 1 Share subscribed under the Shortfall Placement (**Option Fee**); or
- a combination of the Cash Fee and the Option Fee.

The Selling Fee includes all fees payable to other brokers by the Lead Manager under the Shortfall Placement.

**-ENDS**

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

### U.S. Media Contact:

Matthew Wygant

[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)

+1-408-905-7630

### Australian Media & Investor Relations:

Matt Wright, NWR Communications

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

+61-451-896-420

**Imagion Biosystems Limited**

ACN 616 305 027

Level 8, 555 Bourke Street, Melbourne VIC 3000

[www.imagionbiosystem.com](http://www.imagionbiosystem.com)